You just read:

OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion of Final Futility Survival Analysis

News provided by

OncoGenex Pharmaceuticals, Inc.

Jul 13, 2015, 07:00 ET